Telix Pharmaceuticals (TLX) said late Monday that part 1 of a phase 3 trial of TLX591-Tx in patients with metastatic castration resistant prostate cancer achieved its primary objectives.
Results of the study showed an acceptable safety and tolerability profile with no new safety signals observed, the company said.
Telix also said it has advanced the study into part 2.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.